These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39362994)

  • 1. Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia.
    Verbeek TCAI; Vrenken KS; Arentsen-Peters STCJM; Castro PG; van de Ven M; van Tellingen O; Pieters R; Stam RW
    Commun Biol; 2024 Oct; 7(1):1257. PubMed ID: 39362994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin enhances the efficacy of cytarabine
    Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
    Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
    [No Abstract]   [Full Text] [Related]  

  • 3. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in
    Adriaanse FRS; Schneider P; Arentsen-Peters STCJM; Fonseca AMND; Stutterheim J; Pieters R; Zwaan CM; Stam RW
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
    Kwon MC; Thuring JW; Querolle O; Dai X; Verhulst T; Pande V; Marien A; Goffin D; Wenge DV; Yue H; Cutler JA; Jin C; Perner F; Hogeling SM; Shaffer PL; Jacobs F; Vinken P; Cai W; Keersmaekers V; Eyassu F; Bhogal B; Verstraeten K; El Ashkar S; Perry JA; Jayaguru P; Barreyro L; Kuchnio A; Darville N; Krosky D; Urbanietz G; Verbist B; Edwards JP; Cowley GS; Kirkpatrick R; Steele R; Ferrante L; Guttke C; Daskalakis N; Pietsch EC; Wilson DM; Attar R; Elsayed Y; Fischer ES; Schuringa JJ; Armstrong SA; Packman K; Philippar U
    Blood; 2024 Sep; 144(11):1206-1220. PubMed ID: 38905635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
    Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency.
    Sheridan M; Maqbool MA; Largeot A; Clayfield L; Xu J; Moncaut N; Sellers R; Whittle J; Paggetti J; Iqbal M; Aucagne R; Delva L; Baker SM; Lie-A-Ling M; Kouskoff V; Lacaud G
    J Hematol Oncol; 2024 Oct; 17(1):91. PubMed ID: 39380002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia.
    Yin L; Wan L; Zhang Y; Hua S; Shao X
    Cancer Med; 2024 Oct; 13(20):e70326. PubMed ID: 39428967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
    Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
    Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in
    Fournier E; Inchiappa L; Delattre C; Pignon JM; Danicourt F; Bemba M; Roche-Lestienne C; Daudignon A; Decool G; Roumier C; Dumezy F; Fournier L; Grardel N; Preudhomme C; Duployez N
    Leuk Lymphoma; 2019 Jul; 60(7):1827-1830. PubMed ID: 30616415
    [No Abstract]   [Full Text] [Related]  

  • 12. [Progress of allogeneic hematopoietic stem cell transplantation in KMT2A-rearranged acute leukemia].
    Liu J; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):514-520. PubMed ID: 38964931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
    Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
    Front Oncol; 2022; 12():863329. PubMed ID: 35677155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases.
    Vega-García N; Malatesta R; Estella C; Pérez-Jaume S; Esperanza-Cebollada E; Torrebadell M; Català A; Gassiot S; Berrueco R; Ruiz-Llobet A; Alonso-Saladrigues A; Mesegué M; Pont-Martí S; Rives S; Camós M
    Br J Haematol; 2018 Aug; 182(4):542-553. PubMed ID: 29978456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
    Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
    Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pediatric case of
    Murphy L; Siegele B; Carstens B; Hartman L; Faulk K
    Leuk Lymphoma; 2024 Jun; 65(6):843-847. PubMed ID: 38372299
    [No Abstract]   [Full Text] [Related]  

  • 19. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.
    Stumpel DJ; Schneider P; Seslija L; Osaki H; Williams O; Pieters R; Stam RW
    Leukemia; 2012 Apr; 26(4):682-92. PubMed ID: 22015773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.
    Zhang W; Guan Y; Bayliss G; Zhuang S
    Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1015-F1026. PubMed ID: 33017186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.